- Home
- PHI vs VKTX Comparison
PHI vs VKTX Comparison
Compare PHI & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHI
- VKTX
- Stock Information
- Founded
- PHI 1928
- VKTX 2012
- Country
- PHI Philippines
- VKTX United States
- Employees
- PHI N/A
- VKTX N/A
- Industry
- PHI Telecommunications Equipment
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PHI Telecommunications
- VKTX Health Care
- Exchange
- PHI Nasdaq
- VKTX Nasdaq
- Market Cap
- PHI 4.8B
- VKTX 4.7B
- IPO Year
- PHI 1953
- VKTX 2015
- Fundamental
- Price
- PHI $22.38
- VKTX $32.65
- Analyst Decision
- PHI
- VKTX Strong Buy
- Analyst Count
- PHI 0
- VKTX 12
- Target Price
- PHI N/A
- VKTX $106.75
- AVG Volume (30 Days)
- PHI 78.9K
- VKTX 4.1M
- Earning Date
- PHI 11-12-2024
- VKTX 02-05-2025
- Dividend Yield
- PHI 7.55%
- VKTX N/A
- EPS Growth
- PHI 147.52
- VKTX N/A
- EPS
- PHI 2.21
- VKTX N/A
- Revenue
- PHI $3,846,163,485.00
- VKTX N/A
- Revenue This Year
- PHI $4.78
- VKTX N/A
- Revenue Next Year
- PHI $4.33
- VKTX N/A
- P/E Ratio
- PHI $10.03
- VKTX N/A
- Revenue Growth
- PHI 3.33
- VKTX N/A
- 52 Week Low
- PHI $21.00
- VKTX $20.75
- 52 Week High
- PHI $30.39
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- PHI 48.85
- VKTX 25.74
- Support Level
- PHI $21.73
- VKTX $32.51
- Resistance Level
- PHI $23.05
- VKTX $43.55
- Average True Range (ATR)
- PHI 0.45
- VKTX 2.05
- MACD
- PHI 0.08
- VKTX -0.44
- Stochastic Oscillator
- PHI 48.51
- VKTX 1.27
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line, and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.